Alfonso Mendoza Losana
Professor Alfonso Mendoza Losana
Assistant Professor, Department of Microbiology II. Universidad Complutense (Madrid).
Researcher, Head of Molecular Microbiology, Disease of the Developing World (DDW), GSK,
Tres Cantos, Spain. Responsible for COVID-19 activities during 2020 at GSK supporting COVID
clinical trials in collaboration with La Paz and Gregorio Marañón Hospitals, setting up a
Diagnostic Laboratory at GSK and developing medium throughput assays to test GSK
compounds from different chemical projects against SARS-Cov-2 virus. He currently leads the
PBTZ169 (iM4TB) and TAINTTB projects and is a distinguished researcher at the Carlos III
University of Madrid, where he participates in the coordination of the activities of the ERA4TB
consortium. With more than 25 years of experience in antimicrobial drug discovery research in
the private sector, he has published more than 80 articles in indexed journals. GSK
representative in different international collaborative projects, i.e. TB Drug Accelerator funded
by the Bill and Melinda Gates Foundation (B&MGF), European ORCHID project of FP7, NACTAR,
IMI-PreDictTB, and bilateral collaboration with Texas A&M, Weill Cornell Medical College,
Dundee University Drug Discovery Unit. With over 10 years of experience working as Chief
Scientist in GSK's DDW Unit, he has applied core science to identify valuable antimicrobial
targets, develop in vitro and ex vivo assays with high performance potential and has identified
and patented novel antituberculars and new approaches to reduce the incidence of malaria,
progressing several compounds to clinical trials, as well as a new regimen for the treatment of
Buruli ulcer.